loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Balaji Amines Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Balaji Amines Ltd. 04 Aug 2025 12:10 PM
Result PDF

Q1FY26 Quarterly Result Announced for Balaji Amines Ltd.

Specialty Chemicals company Balaji Amines announced Q1FY26 results

  • Revenue from Operations for Q1FY26 stood at Rs 367 crore, as compared to Rs 361 crore in Q4FY25 keeping the performance track intact though the volume growth is seen. The stable commodity prices have allowed us to have the track of performance.
  • Total volumes stood at 27,570 MT for Q1FY26 as against 25,871 MT in Q4FY25. For Q1FY26
    • Amines volumes stood at 7,573 MT.
    • Amines Derivatives volumes stood at 8,108 MT.
    • Specialty Chemicals volumes stood at 11,889 MT.
  • EBITDA for Q1FY26 was Rs 64 crore, as compared to Rs 68 crore in Q4FY25 and Rs 74 crore in Q1FY25.
  • EBITDA margin for Q1FY26 stood at 17% as against 19% in Q4FY25 and 19% in Q1FY25.
  • PAT for Q1FY26 was Rs 37 crore as compared to Rs 40 crore in Q4FY25. Diluted EPS for Q1FY26 stood at Rs 11.73 per equity share as against Rs 12.36 in Q4FY25.

D. Ram Reddy, Managing Director, said: “During Q1FY26, our financial and business performance remained stable, supported by a disciplined working model with stable commodity prices. As volume uptake gradually improves , we anticipate EBITDA and PAT margins to expand, in line with the industry recovery. With the present global and domestic scenario, the utilization of expanded capacities may be impacted in the coming quarters until the basic contribution for our products come through.

At BAL, we remain focused on driving sustainable progress, backed by ongoing investments in key projects and our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade are yet to yield better volumes in serving the domestic market as we have a better product to offer at a competitive pricing, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a stable outlook for short term opportunities, anticipating growth and increased market driven balanced approach for medium to long term with better prospects. As our inherent strengths and competencies position us as a leading force in Amines and Specialty Chemicals, helping us navigate market dynamics and advance towards greater excellence.”

Result PDF

Result PDF

Specialty Chemicals company Balaji Amines announced Q4FY25 & FY25 results

Consolidated Q4FY25 Financial Highlights:

  • Revenue from Operations for Q4FY25 stood at Rs 361 crore, as compared to Rs 321 crore in Q3FY25
  • Total volumes stood at 25,871 MT for Q4FY25 as against 24,107 MT in Q3FY25.
  • EBITDA for Q4FY25 was Rs 68 crore, as compared to Rs 54 crore in Q3FY25 and Rs 106 crore in Q4FY24.
  • EBITDA margin for Q4FY25 stood at 19% as against 17% in Q3FY25 and 25% in Q4FY24.
  • PAT for Q4FY25 was Rs 40 crore as compared to Rs 31 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.36 per equity share as against Rs 10.24 in Q3FY25.

Consolidated FY25 Financial Highlights:

  • Total Income decreased by 14.4%, from Rs 1,671 crore to Rs 1,430 crore.
  • EBITDA declined by 24.9%, from Rs 353 crore to Rs 265 crore.
  • EBITDA Margin fell by 200 bps, from 21% to 19%.
  • PAT dropped by 31.5%, from Rs 232 crore to Rs 159 crore.
  • Sales Volume declined by 4.5%, from 1,09,320 MT to 1,04,393 MT.
  • Cash PAT decreased by 27.5%, from Rs 284 crore to Rs 206 crore.

Standalone Q4FY25 Financial Highlights:

  • Revenue from Operations for Q4FY25 stood at Rs 327 crore, as compared to Rs 305 crore in Q3FY25
  • Total volumes stood at 24,047 MT for Q4FY25 as against 23,447 MT in Q3FY25.
  • EBITDA for Q4FY25 was Rs 64 crore, as compared to Rs 57 crore in Q3FY25 and Rs 95 crore in Q4FY24
  • EBITDA margin for Q4FY25 stood at 20% as against 19% in Q3FY25 and 25% in Q4FY24.
  • PAT for Q4FY25 was Rs 40 crore as compared to Rs 36 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.22 per equity share as against Rs 11.01 in Q3FY25.

Standalone FY25 Financial Highlights:

  • Total Income decreased by 4.6%, from Rs 1,359 crore to Rs 1,296 crore.
  • EBITDA declined by 6.7%, from Rs 267 crore to Rs 249 crore.
  • EBITDA Margin reduced by 100 bps, from 20% to 19%.
  • PAT decreased by 8.8%, from Rs 171 crore to Rs 156 crore.
  • Cash PAT dropped by 4.2%, from Rs 213 crore to Rs 204 crore.
  • Sales Volume increased by 1.5%, from 96,596 MT to 98,086 MT.

On the performance, D. Ram Reddy, Managing Director, commented, “During Q4FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters.

Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned.

On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2 nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.”

Result PDF

Specialty Chemicals company Balaji Amines announced Q3FY25 results

  • Revenue from Operations for Q3FY25 stood at Rs 321 crore, as compared to Rs 356 crore in Q2FY25.
  • Total volumes stood at 24,097 MT for Q3FY25 as against 26,348 MT in Q2FY25.
  • For Q3FY25:
    • Amines volumes stood at 7,515 MT.
    • Amines Derivatives volumes stood at 8,809 MT.
    • Specialty Chemicals volumes stood at 7,773 MT.
  • EBITDA for Q3FY25 was Rs 54 crore, as compared to Rs 70 crore in Q2FY25 and Rs 83 crore in Q3FY24.
  • EBITDA margin for Q3FY24 stood at 17% as against 20% in Q2FY25 and 21% in Q3FY24.
  • PAT for Q3FY25 was Rs 31 crore as compared to Rs 41 crore in Q2FY25.
  • Diluted EPS for Q3FY25 stood at Rs 10.24 per equity share as against Rs 12.65 in Q2FY25.

D. Ram Reddy, Managing Director, said: “During Q3FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement, as some of our products progress through the final approval stages with end-user industries.

This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers.

Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the FY26. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.”

Result PDF

Specialty Chemicals company Balaji Amines announced Q2FY25 results

  • Revenue from Operations for Q2FY25 stood at Rs 356 crore, as compared to Rs 393 crore in Q1FY25
  • Total volumes stood at 26,348 MT for Q2FY25 as against 28,071 MT in Q1FY25. For Q2FY25.
    • Amines volumes stood at 7,616 MT.
    • Amines Derivatives volumes stood at 8,685 MT.
    • Specialty Chemicals volumes stood at 10,046 MT
  • EBITDA for Q2FY25 was Rs 70 crore, as compared to Rs 74 crore in Q1FY25. EBITDA margin for Q2FY24 stood at 20% as against 19% in Q1FY25.
  • PAT for Q2FY25 was Rs 41 crore as compared to Rs 46 crore in Q1FY25. Diluted EPS for Q2FY25 stood at Rs 12.65 per equity share as against Rs 13.36 in Q1FY25.
  • On a standalone basis, we are a zero-debt company.

D. Ram Reddy, Managing Director, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters.

Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence.

As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities. With a clear focus on our strengths, we are set to advance as a leader in Amines and Specialty Chemicals."

Result PDF

Speciality Chemicals company Balaji Amines announced Q4FY24 results:

Financial Highlights:

  • Revenue from Operations for Q4FY24 stood at Rs 423 crore, as compared to Rs 392 crore in Q3FY24.
  • Total volumes stood at 27,984 MT for Q4FY24 as against 26,903 MT in Q3FY24. For Q4FY24,
  • Amines volumes stood at 8,910 MT
  • Amines Derivatives volumes stood at 9,676 MT
  • Specialty Chemicals volumes stood at 9,398 MT
  • EBITDA for Q4FY24 was Rs 106 crore, as compared to Rs 83 crore in Q3FY24. EBITDA margin for Q4FY24 stood at 25% as against 21% in Q3FY24.
  • PAT for Q4FY24 was Rs 72 crore as compared to Rs 56 crore in Q3FY24. Diluted EPS for Q4FY24 stood at Rs 21.00 per equity share as against Rs 15.24 in Q3FY24.
  • On a standalone basis, it is a zero-debt company.

On the performance, D. Ram Reddy, Managing Director, commented, “In Q4 & FY24, our financial and business highlights indicate a positive trajectory, with higher volume uptake, improved EBITDA and PAT margins driven by stabilised input costs(on both raw materials and utilities fronts) and a settling industry scenario. The rebound in domestic demand, coupled with encouraging international market trends, is contributing to this momentum and enhancing our margins.

Recent developments include the successful commencement of n-Butylamines production at Unit-IV, boasting an annual installed capacity of 15,000 MT. Furthermore, Unit-I and Unit-III have received BIS Certification for 'Morpholine,' enhancing our product quality standards.

Both Methylamine and Dimethyl Ether projects are progressing well, showcasing our commitment to operational excellence. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects in the fiscal year 2024- 25. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.”

Result PDF

Specialty Chemicals company Balaji Amines announced Q4FY23 & FY23 results:

  • Consolidated Q4FY23:
    • Revenue from Operations for Q4FY23 stood at Rs 476.90 crore, as compared to Rs 785.41 crore in Q4FY22. Total volumes stood at 26,505 MT for Q4FY23 as against 33,780 MT in Q4FY22.
    • For Q4FY23,
      • Amines volumes stood at 6,659 MT
      • Amines Derivatives volumes stood at 8,607 MT
      • Specialty Chemicals volumes stood at 11,239 MT
    • EBITDA for Q4FY23 was Rs 98.63 crore, as compared to Rs 201.16 crore in Q4FY22. EBITDA margin for Q4FY23 stood at 20.68% as against 25.61% in Q4FY22. The fall in operating margin was primarily on account of degrowth in the pharma and API sector.
    • PAT for Q4FY23 was Rs 55.21 crore, as compared to Rs 130.85 crore in Q4FY22. Diluted EPS for Q4FY23 stood at Rs 14.63 per equity share as against Rs 33.56 in Q4FY22.
  • Consolidated FY23:
    • Revenue from Operations for FY23 stood at Rs 2,370.64 crore, as compared to Rs 2,337.60 crore in FY22. Total volumes stood at 1,10,508 MT for FY23 as against 1,15,349 MT in FY22.
    • For FY23,
      • Amines volumes stood at 25,789 MT
      • Amines Derivatives volumes stood at 33,091 MT
      • Specialty Chemicals volumes stood at 51,628 MT
    • EBITDA for FY23 was Rs 624.36 crore, as compared to Rs 637.39 crore in FY22. EBITDA margin for FY23 stood at 26.34% as against 27.27% in FY22. The fall in operating margin was primarily on account of degrowth in the pharma and API sector.
    • PAT for FY23 was Rs 405.68 crore, as compared to Rs 417.90 crore in FY22. Diluted EPS for FY23 stood at Rs 100.47 per equity share as against Rs 113.71 in FY22.

On the performance, D. Ram Reddy, Managing Director, commented, "Despite headwinds in pharma API and Agro industries globally, we have delivered decent results. The fall in the margins was primarily on account of degrowth in Pharma API and Agro sector. We believe the performance of the company will improve gradually in the coming months, we anticipate a return to growth & margin levels similar to those achieved before the onset of the COVID-19 pandemic in due course, which we think is sustainable. In the past years, we experienced exceptionally high realizations for certain products, driven by global circumstances that have since normalized. Our capex that we had planned was based on the normalized profitability and hence our company will not be impacted adversely by it. In fact, we maintain a positive outlook on the sector and firmly believe in prioritizing growth. We are confident that the products we manufacture have significant demand within India and can effectively substitute imported alternatives. Revenues from the new commenced plants such as DMC, PG, Ethylamines will start contributing to our top line from coming quarters, which in turn can improve the margin profile of the company from Q1FY24.

In the long term we are confident of creating sustainable value for the stakeholders."

 

Result PDF

Specialty chemical firm Balaji Amines announced Q3FY23 results:

  • Consolidated Q3FY23 vs Q3FY22:
    • Revenue from operations for Q3FY23 stood at Rs 588.47 crore, up by 3.48%, as compared to Rs 568.70 crore in Q3FY22. Total volumes stood at 28,147 MT for Q3FY23 as against 27,589 MT in Q3FY22.
    • EBITDA for Q3FY23 was Rs 130.30 crore, as compared to Rs 158.98 crore in Q3FY22. EBITDA margin for Q3FY23 stood at 22.14% as against 27.96% in Q3FY22. The fall in operating margin was primarily on account of degrowth in the pharma and API sector.
    • PAT for Q3FY23 was Rs 83.79 crore, as compared to Rs 101.59 crore in Q3FY22. Diluted EPS for Q3FY23 stood at Rs 19.31 per equity share as against Rs 27.64 in Q3FY22.
  • Q3FY23:
    • Amines volumes stood at 6,082 MT.
    • Amines derivatives volumes stood at 8,587 MT.
    • Specialty chemicals volumes stood at 13,478 MT.

On the performance Mr. D. Ram Reddy, Managing Director, commented, despite headwinds in pharma and API industries globally, we have delivered decent results. The fall in the margins was primarily on account of degrowth in the pharma and API sector.

Revenues from the newly commenced plants will start contributing to our top line in the coming quarters, which in turn can improve the margin profile of the company from Q1FY24.

As announced earlier, Phase 1 of the 90-acre Greenfield Project (Unit IV) has been completed where Ethylamines Plant with an installed annual production capacity of 16,500 tons started commercial production in May 2021 and the DMC/PC and PG Plant started commercial production at the end of September 2022. This is with an installed annual production capacity of 15,000 tons of Di-methyl Carbonate (DMC)/Propylene Carbonate (PC) and 15,000 tons of Propylene Glycol (PG). We believe this will also provide a strategic advantage of being the sole manufacturer of Dimethyl Carbonate (DMC) and Propylene Carbonate (PC) in India. Currently, the annual domestic demand for Dimethyl Carbonate (DMC) is about 6,000 to 8,000 tons with main usage in Pharma and others Annual demand for Propylene Glycol (PG) is about 1,70,000 to 1,80,000 tons & Propylene Carbonate (PC) is about 3,000 to 4,000 tons which are completely met by imports. DMC is used in Pharma and in the production of Polycarbonate and Lithium Batteries – the consumption of which will exponentially grow in India backed by various government initiatives and the EV industry is a sunrise industry in the years to come.

Result PDF

Specialty chemicals company Balaji Amines announced Q2FY23 results:

  • Revenue from Operations for Q2FY23 stood at Rs 630.41 crore, up by 18.95%, compared to Rs 529.99 crore in Q2FY22. Total volumes stood at 28,498 MT in Q2FY23, against 28,360 MT in Q2FY22.
  • EBITDA for Q2FY23 was Rs 175.96 crore, up by 31.06%, compared to Rs 134.26 crore in Q2FY22. EBITDA margin for Q2FY23 stood at 27.91%, against 25.33% in Q2FY22. The improvement in operating margins was primarily on account of better product mix.
  • PAT for Q2FY23 was Rs 118.64 crore, up by 34.71%, compared to Rs 88.07 crore in Q2FY22.
  • Diluted EPS for Q2FY23 stood at Rs 28.57 per equity share, against Rs 24.61 in Q2FY22.

On the performance, Mr. D Ram Reddy, Managing Director, commented, "Despite headwinds in pharma and API industries globally, we have delivered decent quarterly results. The improvement in the margins was primarily on the account of better product mix. Additionally, some of the older plants along with newly started plants had improved capacity utilisation, which resulted in better operating leverage. Revenues from the new plants will start contributing to our top line in the coming quarters, which in turn can improve the margin profile of the company.

As announced earlier, phase 1 of the 90-acre Greenfield Project (Unit IV) has been completed and the DMC/PC and PG Plant started commercial production by the end of September 2022. This is with installed annual production capacity of 15,000 tons of Dimethyl Carbonate (DMC)/Propylene Carbonate (PC) and 15,000 tons Propylene Glycol (PG). We believe this will also provide a strategic advantage of being the sole manufacturer of Dimethyl Carbonate (DMC) and Propylene Carbonate (PC) in India. Currently the annual domestic demand of Di-methyl Carbonate (DMC) is about 8,000 to 9,000 tons with main usage in Pharma and others, Propylene Glycol (PG) is about 170,000 to 180,000 tons & Propylene Carbonate (PC) is about 3,000 to 4,000 tons, which are completely met by imports. DMC is used in pharma and also in the production of Polycarbonate and Lithium Batteries – the consumption of which will exponentially grow in India, backed by various government initiatives. In the first year of operations, the company is confident of achieving capacity utilization of 60-70% at the DMC/PC and PG plant.

In addition to commencement of the installed capacity mentioned above, the company has also started construction for Methyl Amine.

Environmental Clearance for the same has been received well in advance. The company expects to start operations at these state-of-the-art manufacturing facilities around the closure of this financial year

Coming to our capex plans for the future growth journey, we would start initiating capex for installation of the below plants in FY23 and FY24 subject to the Government approvals / permissions / environment clearance:

1) Methylamine plant with a capacity of 40,000 tons
2) N-Butylamines plant with a capacity of 15,000 tons per annum
3) DMAHCL plant with a capacity of 12,000 tons
4) Acetonitrile plant with a capacity of 15,000 tons and
5) DMF plant with a capacity of 30,000 tons

The total capex over FY23 and FY24 will be about Rs 300-350 crore. The production at above plants will commence between mid FY24 till end of FY25 subject to the Government approvals / permissions / environment clearance. 

For our new Acetonitrile plant, we plan to undertake production through a new upgraded technology, where we envisage to have cost advantage, which will enable us to withstand higher prices of acetic acid and shall lead to healthy operating margins. Over medium to long-term we foresee a substantial demand for this product as ‘China Plus One’ strategy takes centre stage and the PLI incentives provided by the Government of India gives further impetus leading to substantial capex by pharmaceutical and agrochemical companies.

Upon smoother accessibility of raw materials for matching products at our clients’ end in coming quarters, we expect to witness an increase in capacity utilization for our legacy products in FY23. We expect substantial improvement in volume offtake in FY23 from improved capacity utilization at our various plants.”

 

Result PDF

Specialty Chemicals firm Balaji Amines announced Q1FY23 Result :

  • Consolidated Q1FY23 Revenue up by 48.86% at Rs 674.86 Crore.
  • EBITDA up by 52.11% at Rs 219.48 Crore.
  • Net Profit up by 51.99% at Rs 148.04 Crore
  • Revenue from Operations for Q1FY23 stood at Rs 674.86 crore, up by 48.86%, as compared to Rs 453.35 crore in Q1FY22. Total volumes stood at 27,358 MT for Q1FY23 as against 25,620 MT in Q1FY22. The revenue growth was on account of improved volume offtake on account of enhanced capacity utilization of our DMF and new Ethylamines plant.
  • Amines volumes stood at 6,739 MT
  • Amines Derivatives volumes stood at 8,128 MT
  • Specialty Chemicals volumes stood at 12491 MT
  • EBITDA for Q1FY23 was Rs 219.48 crore, up by 52.11%, as compared to Rs 144.29 crore in Q1FY22. EBITDA margin for Q1FY23 stood at 32.52% as against 31.83% in Q1FY22. The improvement in operating margins was primarily on account of better product mix, continuing healthier price realizations across most of the products and increase in operating leverage due to surge in volume offtake
  • PAT for Q1FY23 was Rs 148.04 crore, up by 51.99%, as compared to Rs 97.40 crore in Q1FY22.
  • Diluted EPS for Q1FY23 stood at Rs 37.95 per equity share as against Rs 27.90 in Q1FY22.

On the performance Mr. D. Ram Reddy, Managing Director, commented, “In an environment, where the chemical industry is facing major margin pressures due to inflated raw material prices and other costs, we are pleased to have delivered decent quarterly results. In this endeavour, we were aided by improved operating leverage, as our new Ethylamines plants have been running at much improved capacity utilization as compared to previous quarters."

Result PDF

Specialty Chemicals company Balaji Amines declares Q3FY22 result:

  • Consolidated Q3FY22 Revenue up by 44% at Rs 565.83 Crore;
  • EBITDA up by 35% at Rs 159.67 Crore;
  • Net Profit up by 29% at Rs 101.59 Crore
  • Revenue from Operations for Q3FY22 stood at Rs 565.83 crore, up by 44.11%, as compared to Rs 392.64 crore in Q3FY21. Total volumes stood at 27,589 MT for Q3FY22 as against 31,993 MT in Q3FY21. The revenue growth was muted sequentially as compared to previous quarter due to sluggish demand for few products - because few of our clients couldn’t procure Key Starting Materials (KSMs) for some of our matching products.
  • At the same time, the company had to shut down the plants of DMF & Acetonitrile for a brief period to carry out the de-bottlenecking exercise, which were completed in the month of November 2021
  • Amines volumes stood at 6,460 MT
  • Amines Derivatives volumes stood at 9,912 MT
  • Specialty Chemicals volumes stood at 11,217 MT
  • EBITDA for Q3FY22 was Rs 159.67 crore, up by 35.45%, as compared to Rs 117.88 crore in Q3FY21. EBITDA margin for Q3FY22 stood at 28.22% as against 30.02% in Q3FY21. The fall in operating margin was primarily due to lower operating leverage on account of dip in volume offtake
  • PAT for Q3FY22 was Rs 101.59 crore, up by 28.74%, as compared to Rs 78.91 crore in Q3FY21. Diluted EPS for Q3FY22 stood at Rs 27.64 per equity share

On the performance Mr. D. Ram Reddy, Managing Director, commented, “The demand remained sluggish due to the unavailability of KSMs for same of our matching products at our customers’ end in Q3FY22. However, this constraint is now over, and we are witnessing a substantial pick-up in these products. Our sales volumes were also affected on account of temporary shutdowns we had to undertake at our DMF and Acetonitrile plants for the debottlenecking exercise, which was completed in November 2021.

As announced earlier, our capex for DMC plant under Phase 1 of our 90-acre Greenfield Project (Unit IV) is nearing completion and we hope to commence operations during Q1FY23. The capacity of this plant would be about 10,000 to 12,000 tons per annum. The company would be the sole manufacturer of this product in India and currently the annual domestic demand stands at about 8,000 to 9,000 tons which is completely met by imports. We are confident to achieve capacity utilization of 60-70% at our DMC plant in our first year of operation itself. DMC is used in the production of Polycarbonate and Lithium Batteries – the consumption of which will exponentially grow in India backed by various government incentives. Also, we see encouraging scope for exporting DMC to outside markets."

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status